Generation Bio Co. (NASDAQ:GBIO) Short Interest Down 6.1% in September

by · The Cerbat Gem

Generation Bio Co. (NASDAQ:GBIO – Get Free Report) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 2,010,000 shares, a drop of 6.1% from the September 15th total of 2,140,000 shares. Approximately 4.1% of the company’s stock are sold short. Based on an average trading volume of 104,700 shares, the short-interest ratio is currently 19.2 days.

Hedge Funds Weigh In On Generation Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GBIO. Los Angeles Capital Management LLC lifted its stake in Generation Bio by 38.4% during the 1st quarter. Los Angeles Capital Management LLC now owns 381,661 shares of the company’s stock valued at $1,553,000 after acquiring an additional 105,827 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Generation Bio during the first quarter valued at approximately $74,000. PFG Advisors purchased a new stake in Generation Bio in the first quarter worth approximately $41,000. Vanguard Group Inc. grew its position in Generation Bio by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,570,456 shares of the company’s stock worth $10,462,000 after purchasing an additional 18,205 shares during the period. Finally, Acadian Asset Management LLC raised its stake in Generation Bio by 113.9% during the 1st quarter. Acadian Asset Management LLC now owns 479,835 shares of the company’s stock valued at $1,952,000 after buying an additional 255,468 shares during the last quarter. 95.22% of the stock is owned by institutional investors.

Generation Bio Price Performance

Generation Bio stock traded up $0.04 during mid-day trading on Wednesday, reaching $2.46. The stock had a trading volume of 112,779 shares, compared to its average volume of 186,276. Generation Bio has a one year low of $0.86 and a one year high of $4.65. The company has a 50-day moving average price of $2.50 and a two-hundred day moving average price of $2.89. The company has a market capitalization of $163.66 million, a price-to-earnings ratio of -0.96 and a beta of 2.80.

Generation Bio (NASDAQ:GBIO – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The firm had revenue of $4.09 million during the quarter, compared to the consensus estimate of $3.23 million. Generation Bio had a negative return on equity of 92.86% and a negative net margin of 1,202.56%. On average, equities research analysts anticipate that Generation Bio will post -1.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Wedbush restated an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a report on Thursday, August 8th. Needham & Company LLC restated a “buy” rating and issued a $10.00 price target on shares of Generation Bio in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.50.

Check Out Our Latest Stock Analysis on Generation Bio

About Generation Bio

(Get Free Report)

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.

See Also